Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Whooping Cough HELP
Based on 2,204 articles published since 2008
||||

These are the 2204 published articles about Whooping Cough that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). 2018

Liang, Jennifer L / Tiwari, Tejpratap / Moro, Pedro / Messonnier, Nancy E / Reingold, Arthur / Sawyer, Mark / Clark, Thomas A. ·Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC. · Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC. · Office of the Director, National Center for Immunization and Respiratory Diseases, CDC. · University of California, Berkeley; Berkeley, CA. · University of California, San Diego; La Jolla, California. · Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC. ·MMWR Recomm Rep · Pubmed #29702631.

ABSTRACT: This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) regarding prevention and control of tetanus, diphtheria, and pertussis in the United States. As a comprehensive summary of previously published recommendations, this report does not contain any new recommendations and replaces all previously published reports and policy notes; it is intended for use by clinicians and public health providers as a resource. ACIP recommends routine vaccination for tetanus, diphtheria, and pertussis. Infants and young children are recommended to receive a 5-dose series of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccines, with one adolescent booster dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Adults who have never received Tdap also are recommended to receive a booster dose of Tdap. Women are recommended to receive a dose of Tdap during each pregnancy, which should be administered from 27 through 36 weeks' gestation, regardless of previous receipt of Tdap. After receipt of Tdap, adolescents and adults are recommended to receive a booster tetanus and diphtheria toxoids (Td) vaccine every 10 years to assure ongoing protection against tetanus and diphtheria.

2 Guideline Committee Opinion No. 718: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. 2017

Anonymous620917. · ·Obstet Gynecol · Pubmed #28832489.

ABSTRACT: The overwhelming majority of morbidity and mortality attributable to pertussis infection occurs in infants who are 3 months and younger. Infants do not begin their own vaccine series against pertussis until approximately 2 months of age. This leaves a window of significant vulnerability for newborns, many of whom contract serious pertussis infections from family members and caregivers, especially their mothers, or older siblings, or both. In 2013, the Advisory Committee on Immunization Practices published its updated recommendation that a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) should be administered during each pregnancy, irrespective of the prior history of receiving Tdap. The recommended timing for maternal Tdap vaccination is between 27 weeks and 36 weeks of gestation. To maximize the maternal antibody response and passive antibody transfer and levels in the newborn, vaccination as early as possible in the 27-36-weeks-ofgestation window is recommended. However, the Tdap vaccine may be safely given at any time during pregnancy if needed for wound management, pertussis outbreaks, or other extenuating circumstances. There is no evidence of adverse fetal effects from vaccinating pregnant women with an inactivated virus or bacterial vaccine or toxoid, and a growing body of robust data demonstrate safety of such use. Adolescent and adult family members and caregivers who previously have not received the Tdap vaccine and who have or anticipate having close contact with an infant younger than 12 months should receive a single dose of Tdap to protect against pertussis. Given the rapid evolution of data surrounding this topic, immunization guidelines are likely to change over time, and the American College of Obstetricians and Gynecologists will continue to issue updates accordingly.

3 Guideline Committee Opinion No. 718 Summary: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. 2017

Anonymous530917. · ·Obstet Gynecol · Pubmed #28832480.

ABSTRACT: The overwhelming majority of morbidity and mortality attributable to pertussis infection occurs in infants who are 3 months and younger. Infants do not begin their own vaccine series against pertussis until approximately 2 months of age. This leaves a window of significant vulnerability for newborns, many of whom contract serious pertussis infections from family members and caregivers, especially their mothers, or older siblings, or both. In 2013, the Advisory Committee on Immunization Practices published its updated recommendation that a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) should be administered during each pregnancy, irrespective of the prior history of receiving Tdap. The recommended timing for maternal Tdap vaccination is between 27 weeks and 36 weeks of gestation. To maximize the maternal antibody response and passive antibody transfer and levels in the newborn, vaccination as early as possible in the 27-36-weeks-of-gestation window is recommended. However, the Tdap vaccine may be safely given at any time during pregnancy if needed for wound management, pertussis outbreaks, or other extenuating circumstances. There is no evidence of adverse fetal effects from vaccinating pregnant women with an inactivated virus or bacterial vaccine or toxoid, and a growing body of robust data demonstrate safety of such use. Adolescent and adult family members and caregivers who previously have not received the Tdap vaccine and who have or anticipate having close contact with an infant younger than 12 months should receive a single dose of Tdap to protect against pertussis. Given the rapid evolution of data surrounding this topic, immunization guidelines are likely to change over time, and the American College of Obstetricians and Gynecologists will continue to issue updates accordingly.

4 Guideline Finnish guidelines for the treatment of community-acquired pneumonia and pertussis in children. 2016

Tapiainen, Terhi / Aittoniemi, Janne / Immonen, Johanna / Jylkkä, Heli / Meinander, Tuula / Nuolivirta, Kirsi / Peltola, Ville / Salo, Eeva / Seuri, Raija / Walle, Satu-Maaria / Korppi, Matti. ·Department of Pediatrics and Adolescence, Oulu University Hospital, Oulu, Finland. · PEDEGO Research Unit - Research Unit for Pediatrics, Dermatology, Clinical Genetics Obstetrics and Gynecology, and Medical Research Center, University of Oulu, Finland. · Fimlab Laboratories, Tampere, Finland. · Terveystalo Pediatric Clinic, Kuopio, Finland. · Department of Pediatrics, University of Tampere, Tampere, Finland. · Department of Internal Medicine, Tampere University Hospital and the Finnish Medical Society Duodecim, Tampere, Finland. · Seinäjoki Central Hospital, Seinäjoki, Finland. · Department of Pediatrics, Turku University Hospital and University of Turku, Turku, Finland. · Department of Pediatrics, Helsinki University Hospital, Helsinki, Finland. · HUS Imaging, Children's Hospital, Helsinki University Hospital, Helsinki, Finland. · Espoonlahti Health Care Center, Espoo, Finland. · Department of Pediatrics, Tampere University Hospital and University of Tampere, Tampere, Finland. ·Acta Paediatr · Pubmed #26341383.

ABSTRACT: CONCLUSION: The clinical guidelines state that chest radiography is not needed if the child is diagnosed with pneumonia and treated at home. Complications should be considered if there is no improvement after antimicrobial therapy and a paroxysmal cough can indicate pertussis, which is life-threatening in unvaccinated infants and can lead to respiratory failure.

5 Guideline [Haut Conseil de la santé publique (HCSP). Management of single or multiple pertussis cases]. 2015

Anonymous5440832. ·14, avenue Duquesne, 75350 Paris 07 SP, France. Electronic address: http://www.hcsp.fr. ·Rev Mal Respir · Pubmed #26054984.

ABSTRACT: -- No abstract --

6 Guideline Revised guidance on the choice of pertussis vaccines: July 2014. 2014

Anonymous4990801. · ·Wkly Epidemiol Rec · Pubmed #25072068.

ABSTRACT: -- No abstract --

7 Guideline Pertussis vaccination of health care workers: ACOEM medical center occupational health section task force on pertussis vaccination of health care workers. 2013

Russi, Mark / Behrman, Amy / Buchta, William G / Budnick, Lawrence D / Hodgson, Michael J / Spillmann, Scott J / Swift, Melanie D / Anonymous340769. · ·J Occup Environ Med · Pubmed #24013658.

ABSTRACT: -- No abstract --

8 Guideline Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. 2013

Anonymous4420750. · ·MMWR Morb Mortal Wkly Rep · Pubmed #23425962.

ABSTRACT: In October 2011, in an effort to reduce the burden of pertussis in infants, the Advisory Committee on Immunization Practices (ACIP) recommended that unvaccinated pregnant women receive a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). Vaccination of women with Tdap during pregnancy is expected to provide some protection to infants from pertussis until they are old enough to be vaccinated themselves. Tdap given to pregnant women will stimulate the development of maternal antipertussis antibodies, which will pass through the placenta, likely providing the newborn with protection against pertussis in early life, and will protect the mother from pertussis around the time of delivery, making her less likely to become infected and transmit pertussis to her infant. The 2011 Tdap recommendation did not call for vaccinating pregnant women previously vaccinated with Tdap. On October 24, 2012, ACIP voted to recommend use of Tdap during every pregnancy. This report summarizes data considered and conclusions made by ACIP and provides guidance for implementing its recommendations. These updated recommendations on use of Tdap in pregnant women aim to optimize strategies for preventing pertussis morbidity and mortality in infants.

9 Guideline [Whooping cough in Spain. Current epidemiology, prevention and control strategies. Recommendations by the Pertussis Working Group]. 2013

Campins, Magda / Moreno-Pérez, David / Gil-de Miguel, Angel / González-Romo, Fernando / Moraga-Llop, Fernando A / Arístegui-Fernández, Javier / Goncé-Mellgren, Anna / Bayas, José M / Salleras-Sanmartí, Lluís. ·Sociedad Española de Medicina Preventiva, Salud Pública e Higiene, Spain. mcmarti@telefonica.net ·Enferm Infecc Microbiol Clin · Pubmed #23411362.

ABSTRACT: A large increase of pertussis incidence has been observed in recent years in countries with high vaccination coverage. Outbreaks of pertussis are increasingly being reported. The age presentation has a bipolar distribution: infants younger 6months that have not initiated or completed a vaccination schedule, and adolescents and adults, due to the lost of natural or vaccine immunity over time. These epidemiological changes justify the need to adopt new vaccination strategies in order to protect young infants and to reduce pertussis incidence in all age groups. Adolescents and adults immunization must be a priority. In the first group, strategy is easy to implement, and with a very low additional cost (to replace dT vaccine by dTap one). Adult vaccination may be more difficult to implement; dT vaccine decennial booster should be replaced by dTap. The immunization of household contacts of newborn infants (cocooning) is the strategy that has a most important impact on infant pertussis. Recently, pregnant women vaccination (after 20weeks of gestation) has been recommended in some countries as the most effective way to protect the newborn.

10 Guideline Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012. 2012

Anonymous2080730. · ·MMWR Morb Mortal Wkly Rep · Pubmed #22739778.

ABSTRACT: Since 2005, the Advisory Committee on Immunization Practices (ACIP) has recommended a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine booster dose for all adolescents aged 11 through 18 years (preferred at 11 through 12 years) and for those adults aged 19 through 64 years who have not yet received a dose. In October 2010, despite the lack of an approved Tdap vaccine for adults aged 65 years and older, ACIP recommended that unvaccinated adults aged 65 years and older be vaccinated with Tdap if in close contact with an infant, and that other adults aged 65 years and older may receive Tdap. In July 2011, the Food and Drug Administration (FDA) approved expanding the age indication for Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium) to aged 65 years and older. In February 2012, ACIP recommended Tdap for all adults aged 65 years and older. This recommendation supersedes previous Tdap recommendations regarding adults aged 65 years and older.

11 Guideline Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months --- Advisory Committee on Immunization Practices (ACIP), 2011. 2011

Anonymous1300708. · ·MMWR Morb Mortal Wkly Rep · Pubmed #22012116.

ABSTRACT: Compared with older children and adults, infants aged <12 months have substantially higher rates of pertussis and the largest burden of pertussis-related deaths. Since 2004, a mean of 3,055 infant pertussis cases with more than 19 deaths has been reported each year through the National Notifiable Diseases Surveillance System (CDC, unpublished data, 2011). The majority of pertussis cases, hospitalizations, and deaths occur in infants aged ≤2 months, who are too young to be vaccinated; therefore, other strategies are required for prevention of pertussis in this age group. Since 2005, the Advisory Committee on Immunization Practices (ACIP) has recommended tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) booster vaccines to unvaccinated postpartum mothers and other family members of newborn infants to protect infants from pertussis, a strategy referred to as cocooning. Over the past 5 years, cocooning programs have proven difficult to implement widely. Cocooning programs might achieve moderate vaccination coverage among postpartum mothers but have had limited success in vaccinating fathers or other family members. On June 22, 2011, ACIP made recommendations for use of Tdap in unvaccinated pregnant women and updated recommendations on cocooning and special situations. This report summarizes data considered and conclusions made by ACIP and provides guidance for implementing its recommendations.

12 Guideline Adult immunizations: update on recommendations. 2011

Pham, Huan / Geraci, Stephen A / Burton, Mary Jane / Anonymous9600697. ·Division of Infectious Diseases, Department of Medicine, University of Mississippi School of Medicine, Jackson, USA. ·Am J Med · Pubmed #21658665.

ABSTRACT: The Advisory Committee for Immunization Practices recommends universal influenza vaccination for 2010-2011. Older adults should be offered protection against herpes zoster, and younger adults should receive immunization against human papilloma virus and pertussis. Hepatitis B vaccination should be encouraged in non-immune adults. Recommendations also address vaccinations for tetanus/diphtheria, hepatitis A, pneumococcus, measles/mumps/rubella, and meningococcus.

13 Guideline [Consensus on the clinical and microbiologic diagnosis of Bordetella pertussis, and infection prevention. Expert Group on Pertussis Vaccination]. 2011

Anonymous2010687 / Beltrán Silva, Sandra / Cervantes Apolinar, Yolanda / Cherry, James D / Conde González, Carlos / Gentile, Angela / Gómez Altamirano, César Misael / Hernández Porras, Marte / Huerta García, Gloria / Macías Parra, Mercedes / Martínez Aguilar, Gerardo / Mascareñas de los Santos, Abiel / Moreno Espinosa, Sarbelio / Pacheco Ríos, Aarón / Prado Cohrs, David / Rodriguez Weber, Miguel Angel / Romano Mazzotti, Luis / Rosales Uribe, Erick / Sifuentes Osornio, José / Ulloa-Gutiérrez, Rolando / Villaseñor Sierra, Alberto. · ·Salud Publica Mex · Pubmed #21340141.

ABSTRACT: Pertussis continues to be responsible for a significant disease burden worldwide. Although immunization practices have reduced the occurrence of the disease among children, waning vaccine- and infection-induced immunity still allows the disease to affect adolescents and adults who, in turn, can transmit the disease to non-immunized or partially immunized infants. This document is the result of a meeting in Mexico City of international experts who analyzed recent medical information in order to establish the current status of the epidemiology, diagnosis and surveillance of pertussis and, especially, the value of the dTpa booster dose in adolescents and adults as a pertussis prevention strategy in Mexico.

14 Guideline Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. 2011

Anonymous4410683. · ·MMWR Morb Mortal Wkly Rep · Pubmed #21228763.

ABSTRACT: Despite sustained high coverage for childhood pertussis vaccination, pertussis remains poorly controlled in the United States. A total of 16,858 pertussis cases and 12 infant deaths were reported in 2009. Although 2005 recommendations by the Advisory Committee on Immunization Practices (ACIP) called for vaccination with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) for adolescents and adults to improve immunity against pertussis, Tdap coverage is 56% among adolescents and <6% among adults. In October 2010, ACIP recommended expanded use of Tdap. This report provides the updated recommendations, summarizes the safety and effectiveness data considered by ACIP, and provides guidance for implementing the recommendations.

15 Guideline What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. 2011

Guiso, N / Berbers, G / Fry, N K / He, Q / Riffelmann, M / Wirsing von König, C H / Anonymous160679. ·Institut Pasteur, Paris, France. ·Eur J Clin Microbiol Infect Dis · Pubmed #21069406.

ABSTRACT: Bordetella pertussis-specific antibodies can be detected by enzyme-linked immunosorbent assays (ELISAs) or multiplex immunoassays. Assays use purified or mixed antigens, and only pertussis toxin (PT) is specific for B. pertussis. The interpretation of results can be based on dual-sample or single-sample serology using one or two cut-offs. The EU Pertstrain group recommends that: (i) ELISAs and multiplex immunoassays should use purified non-detoxified PT as an antigen, that they should have a broad linear range and that they should express results quantitatively in International Units per millilitre (IU/ml); (ii) a single or dual diagnostic cut-off for single-serum serology using IgG-anti-PT between 50 and 120 IU/ml should be used, and diagnostic serology cannot be validly interpreted for one year after vaccination with acellular pertussis (aP) vaccines; (iii) IgA-anti-PT should only be used with indeterminate IgG-anti-PT levels or when a second sample cannot be obtained. This group discourages using: (i) other antigens in routine diagnostics, as they are not specific; (ii) micro-agglutination, due to its lack of sensitivity; (iii) immunoblots for pertussis serodiagnosis, as results cannot be quantified; (iv) other methods, such as complement fixation or indirect immunofluorescence, due to their low sensitivity and/or specificity.

16 Guideline ACOG Committee Opinion No. 438: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. 2009

Anonymous2680634. · ·Obstet Gynecol · Pubmed #19623004.

ABSTRACT: -- No abstract --

17 Guideline Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP). 2008

Murphy, Trudy V / Slade, Barbara A / Broder, Karen R / Kretsinger, Katrina / Tiwari, Tejpratap / Joyce, Patricia M / Iskander, John K / Brown, Kristin / Moran, John S / Anonymous530600. ·Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Atlanta, GA 30333, USA. tkm4@cdc.gov ·MMWR Recomm Rep · Pubmed #18509304.

ABSTRACT: In 2005, two tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines were licensed and recommended for use in adults and adolescents in the United States: ADACEL (sanofi pasteur, Swiftwater, Pennsylvania), which is licensed for use in persons aged 11--64 years, and BOOSTRIX (GlaxoSmithKline Biologicals, Rixensart, Belgium), which is licensed for use in persons aged 10-18 years. Both Tdap vaccines are licensed for single-dose use to add protection against pertussis and to replace the next dose of tetanus and diphtheria toxoids vaccine (Td). Available evidence does not address the safety of Tdap for pregnant women, their fetuses, or pregnancy outcomes sufficiently. Available data also do not indicate whether Tdap-induced transplacental maternal antibodies provide early protection against pertussis to infants or interfere with an infant's immune responses to routinely administered pediatric vaccines. Until additional information is available, CDC's Advisory Committee on Immunization Practices recommends that pregnant women who were not vaccinated previously with Tdap: 1) receive Tdap in the immediate postpartum period before discharge from hospital or birthing center, 2) may receive Tdap at an interval as short as 2 years since the most recent Td vaccine, 3) receive Td during pregnancy for tetanus and diphtheria protection when indicated, or 4) defer the Td vaccine indicated during pregnancy to substitute Tdap vaccine in the immediate postpartum period if the woman is likely to have sufficient protection against tetanus and diphtheria. Although pregnancy is not a contraindication for receiving Tdap vaccine, health-care providers should weigh the theoretical risks and benefits before choosing to administer Tdap vaccine to a pregnant woman. This report 1) describes the clinical features of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants, 2) reviews available evidence of pertussis vaccination during pregnancy as a strategy to prevent infant pertussis, 3) summarizes Tdap vaccination policy in the United States, and 4) presents recommendations for use of Td and Tdap vaccines among pregnant and postpartum women.

18 Editorial Cognitive Development One Year After Infantile Critical Pertussis. 2018

Johnston, Michael V. ·Kennedy Krieger Institute and Johns Hopkins School of Medicine, Baltimore, MD. ·Pediatr Crit Care Med · Pubmed #29394223.

ABSTRACT: -- No abstract --

19 Editorial Pertussis in infants and the resurgence of a vaccine preventable disease: what to do? Commentary. 2017

Fedele, Giorgio / Stefanelli, Paola. ·Dipartimento di Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy. ·Ann Ist Super Sanita · Pubmed #28617254.

ABSTRACT: Pertussis or whooping cough remains one of the most poorly controlled vaccine-preventable diseases across the world. Universal vaccination has dramatically reduced its incidence but has failed to bring it completely under control. In the last decades, changes in pertussis epidemiology have been noted, likely related to the introduction of acellular pertussis vaccines. Increasing incidence is recorded among adolescents and adults who have become a reservoir for transmission to unimmunized infants, who are at risk of severe disease and death. In Italy, experimental evidences suggest a sustained circulation of Bordetella pertussis in the adult population and a significant health burden of pertussis among infants less than six months of age. Public health systems are currently exploring new vaccination strategies, including a cocooning strategy to prevent the transmission of the disease from family members to the newborn and vaccination of pregnant mothers to transmit protective antibodies to the offspring, and neonatal vaccination. An integrated approach for pertussis control and prevention is needed to enhance the current surveillance system and provide an accurate estimate of the real burden of pertussis in our Country, particularly among infants.

20 Editorial Outer membrane vesicles: an attractive candidate for pertussis vaccines. 2017

Hozbor, Daniela F. ·a Laboratorio VacSal , Instituto de Biotecnología y Biología Molecular, Facultad de Ciencias Exactas, Universidad Nacional de La Plata , La Plata , Argentina. ·Expert Rev Vaccines · Pubmed #28010142.

ABSTRACT: -- No abstract --

21 Editorial Critical Pertussis Among Infants-Many More Miles to Go! 2016

Mathew, Joseph L / Singhi, Sunit. ·Department Of Pediatrics & Advanced Pediatrics Centre Postgraduate Institute of Medical Education and Research Chandigarh, India Department Of Pediatrics MM Institute of Medical Science and Research Mullana, Ambala, India. ·Pediatr Crit Care Med · Pubmed #27500616.

ABSTRACT: -- No abstract --

22 Editorial The Pertussis Problem and a Possible Solution: Will Parents Go Along? 2016

Sawyer, Mark H. ·University of California, San Diego School of Medicine, Rady Children's Hospital-San Diego, San Diego. ·JAMA Pediatr · Pubmed #27019461.

ABSTRACT: -- No abstract --

23 Editorial Toward High-Reliability Vaccination Efforts in the United States. 2016

Davis, Matthew M. ·Child Health Evaluation and Research Unit, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor2Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor3Institute for Healthcare Poli. ·JAMA · Pubmed #26978205.

ABSTRACT: -- No abstract --

24 Editorial Pertussis: acellular, whole-cell, new vaccines, what to choose? 2016

Locht, Camille. ·a Univ. Lille, U1019 - UMR 8204 - CIIL , Centre for Infection and Immunity of Lille , Lille , France. · b CNRS , UMR 8204, Lille , France. · c Inserm , U1019, Lille , France. · d CHU Lille , Lille , France. · e Institut Pasteur de Lille , Lille , France. ·Expert Rev Vaccines · Pubmed #26938372.

ABSTRACT: -- No abstract --

25 Editorial EDITORIAL. 2015

John, Joseph F. · ·J S C Med Assoc · Pubmed #27141700.

ABSTRACT: -- No abstract --

Next